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Abstract
Background: Overexpression of ERG transcription factor due to genomic ERG-rearrangements defines a separate molecular
subtype of prostate tumors. One of the consequences of ERG accumulation is modulation of the cell’s gene expression
profile. Tudor domain-containing protein 1 gene (TDRD1) was reported to be differentially expressed between
TMPRSS2:ERG-negative and TMPRSS2:ERG-positive prostate cancer. The aim of our study was to provide a mechanistic
explanation for the transcriptional activation of TDRD1 in ERG rearrangement-positive prostate tumors.
Methodology/Principal Findings: Gene expression measurements by real-time quantitative PCR revealed a remarkable co-
expression of TDRD1 and ERG (r2 = 0.77) but not ETV1 (r2,0.01) in human prostate cancer in vivo. DNA methylation analysis
by MeDIP-Seq and bisulfite sequencing showed that TDRD1 expression is inversely correlated with DNA methylation at the
TDRD1 promoter in vitro and in vivo (r=20.57). Accordingly, demethylation of the TDRD1 promoter in TMPRSS2:ERG-
negative prostate cancer cells by DNA methyltransferase inhibitors resulted in TDRD1 induction. By manipulation of ERG
dosage through gene silencing and forced expression we show that ERG governs loss of DNA methylation at the TDRD1
promoter-associated CpG island, leading to TDRD1 overexpression.
Conclusions/Significance: We demonstrate that ERG is capable of disrupting a tissue-specific DNA methylation pattern at
the TDRD1 promoter. As a result, TDRD1 becomes transcriptionally activated in TMPRSS2:ERG-positive prostate cancer. Given
the prevalence of ERG fusions, TDRD1 overexpression is a common alteration in human prostate cancer which may be
exploited for diagnostic or therapeutic procedures.
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Introduction
Approximately half of human prostate cancer cases identified by
PSA-screening harbor genomic rearrangements in which androgen-
responsive regulatory elements are juxtaposed to genes coding for
transcription factors of the ETS family [1–3]. As a result, ETS genes
become coupled to androgen receptor (AR) signaling and are
overexpressed in fusion-positive prostate tumors [4–6]. The most
prevalent of these genomic rearrangements, the TMPRSS2:ERG
gene fusion, leads to a strong overexpression of the ERG
transcription factor which is otherwise absent in cells of the prostate
epithelium [7]; under physiological conditions ERG displays a tissue-
restricted expression pattern and is transcribed in the hematopoietic
linage [8] and endothelial cells [9]. The question of how ERG
accumulation influences the biology of prostate cancer cells in vitro
and in vivo has gained a significant interest. Until now, ERG was
suggested to modulate the phenotype of prostate cancer cells by a
wide range of processes, including: disruption of AR signaling [10],
activation of c-myc signaling [11] and estrogen receptor network
[12], activation of the Wnt pathway and induction of epithelial-to-
mesenchymal transition [13], promotion of cell invasion [14],
physical interaction with PARP1 [15] and activation of TGF-b/
BMP signaling [16]. Tumors harboring the ERG fusion were also
found to be enriched for loss of the PTEN tumor suppressor [17,18].
Accordingly, in mouse models of prostate cancer ERGwas shown to
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cooperate with PI3K pathway to drive carcinogenesis [19,20].
Accumulation of ERG was also found to be associated with an
altered DNA methylation pattern in prostate cancer cells
[10,21,22]. Analysis of the prostate cancer transcriptome performed
by us and others demonstrated that tumors harboring the
TMPRSS2:ERG fusion share a unique gene expression profile
which significantly differs from profiles of benign prostate tissue and
malignant tumors lacking the fusion [1,10,12,13,16,23]. Specifical-
ly, tumors overexpressing ERG are characterized by transcriptional
modulation of genes involved in the Wnt and TGF-b/BMP
pathways [16], b-estradiol network [12,23] and NF-kB pathway
[24].
Among genes deregulated in ERG-rearranged prostate cancer, at
least two independent studies identified Tudor domain-containing
protein 1 (TDRD1) as the most differentially expressed gene
between ERG rearrangement-positive and -negative prostate
cancer, apart from ERG itself [16,23]. Similarly to ERG, TDRD1
is not transcribed in normal prostate epithelium [25,26]. TDRD1
has been initially identified as a cancer/testis antigen, i.e. a gene
which is expressed in the testis and cancer, but silent in adult
somatic tissues [26]. Its mouse ortholog, Tdrd1, is expressed during
spermatogenesis where it acts in the conserved piRNA pathway to
repress the activity of LINE1 retrotransposons by methylation [27].
A recent study in zebrafish suggested that Tdrd1 acts as a molecular
scaffold for Piwi proteins, piRNAs and piRNA targets [28]. In both
mouse and zebrafish, Tdrd1 is required for a correct function of the
piRNA pathway and Tdrd1 knockout in mouse results in a defective
spermatogenesis [28,29].
Here, we report that ERG and TDRD1 are co-expressed in
human prostate cancers and we provide a mechanistic explanation
for the observed co-expression. We demonstrate that ERG
activates TDRD1 transcription by inducing loss of DNA methyl-
ation at the TDRD1 promoter-associated CpG island. We propose
that this epigenetic consequence of the TMPRSS2:ERG fusion
represents a novel mechanism which may explain part of the




Prostate tissue samples were obtained from the University
Medical Center Hamburg Eppendorf. Approval for the study was
obtained from the local ethics committee and all patients agreed to
additional tissue sampling for scientific purposes.
Prostate Tissue Samples, Genome-wide Expression
Profiling and Methylation Analysis
Details of human samples collection, extraction of RNA,
conversion to cDNA and genome-wide expression profiling are
described elsewhere [16]. DNA extraction and genome-wide
methylation analysis by MeDIP-Seq are described elsewhere [22].
The data from genome-wide expression profiling and genome-
wide methylation analysis are publicly available in the Gene
Expression Omnibus database (accession numbers GSE29079 and
GSE35342). TMPRSS2:ERG fusion status was determined by PCR
using previously described primers [30] and by qPCR [16].
Samples, for which both mRNA expression and DNA methylation
data were available, were included in the analysis.
Cell Culture
VCaP, NCI-H660, LNCaP, DU145, PC-3, and RWPE-1 cells
were obtained from ATCC (Manassas, VA, USA). BPH-1 cells
were a kind gift of Doris Mayer (DKFZ, Heidelberg). K-562 and
KG-1 cells were provided by Christoph Plass and Peter Krammer,
respectively (DKFZ, Heidelberg). MOLT4 and CMK cells were
obtained from DSMZ (Braunschweig, Germany). VCaP cells were
maintained in DMEM medium (Gibco, Life Technologies,
Carlsbad, CA, USA) supplemented with 10% FBS (Gibco).
NCI-H660 cells were cultured in RPMI-1640 (Gibco) supple-
mented with 5% FBS (Gibco), 2 mM L-gluatmine, 0.005 mg/ml
insulin, 0.01 mg/ml transferrin, 30 nM sodium selenite, 10 nM
hydrocortisone and 10 nM beta-estradiol (all from Sigma-Aldrich,
St Louis, MO, USA). LNCaP and DU145 were maintained in
RPMI-1640 (Gibco) supplemented with 10% FBS. PC-3 cells were
cultured in F12-K medium (ATCC) supplemented with 10% FBS.
RWPE1 cells were cultured in keratinocyte serum-free medium
supplemented with 0.05 mg/ml bovine pituary extract and 5 ng/
ml recombinant EGF (Gibco). BPH1 cells were cultured in RPMI-
1640 medium (Gibco) supplemented with 10% FBS and 20 ng/
mL 5a-dihydrotestosterone (Sigma). K-562 and MOLT-4 cells
were cultured in RPMI-1640 and supplemented with 10% heat-
inactivated FBS, KG-1 and CMK cells were cultured in RPMI-
1640 supplemented with 20% heat-inactivated FBS.
Generation of Stable LNCaP Clones and Induction of
Transgene Expression
ERG coding sequence (exons 4–11 from NM_004449.3), which
corresponds to TMPRSS2:ERG fusion T1/E4 [31], was amplified
from NM_004449.3-containing plasmid (Genomics and Proteo-
mics Core Facility, DKFZ ) by PCR using primers: forward
GCAGGCTCCACCATGACCGCGTCCTCCTCCAG, reverse
CAAGAAAGCTGGGTCTTAGTAGTAAGTGCCCAGAT.
Stably transfected LNCaP clones were generated as previously
described [32]. Transgene expression was induced with 50 ng/ml
doxycycline (Sigma).
RNA Extraction and Reverse Transcription
Total RNA was isolated from exponentially growing cell lines
using RNeasy Mini Kit (Qiagen, Hilden, Germany) following the
manufacturer’s instruction. cDNA synthesis was performend using
SuperScript III reverse transcriptase (Life Technologies) and oligo-
dT primers (Sigma-Aldrich) following manufacturers’ instructions.
For the measurement of LINE1-ORF2 mRNA, total RNA was
treated with Turbo DNase (Life Technologies) to remove the
contaminating genomic DNA. DNase-treated RNA was then
purified using RNeasy MinElute Cleanup Kit (Qiagen) and
subjected to reverse transcription using RevertAid H Minus First
Strand cDNA Synthesis Kit (Fermentas, Burlington, Canada) and
random hexamer primers.
Quantitative RT-PCR
Gene expression levels were measured on the LightCycler 480
Real-Time PCR System (Roche, Mannheim, Germany). cDNA
equivalent of 10 ng total RNA was used per well. All measure-
ments were performed in triplicate. Taqman assays (Applied
Biosystems) were run with 2x ABsolute QPCR Mix (Abgene,
Thermo Fischer, Epsom, UK). Universal Probe Library (UPL)
system assays (Roche) were run using 480 Probes Master (Roche).
Raw Cp values were calculated by the Roche Lightcycler 480
software using the 2nd derivative maximum method. Assays and
primer sequences are listed in the Table S1 together with the
corresponding figure numbers. Expression levels are presented as
absolute values (Cp) or as expression relative to an internal
reference gene (using DCp method).
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Western Blotting
Exponentially-growing cells were lysed with RIPA buffer
(50 mM Tris-HCl pH 8, 150 mM NaCl, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS) supplemented with 5 mM EDTA and
HALT Protease Inhibitor Cocktail (Pierce, Thermo Fisher
Scientific, Rockford, IL). Protein concentrations were determined
with BCA Protein Assay kit (Pierce). Unless stated otherwise,
30 mg of protein lysates were separated in 10% SDS-PAGE gels
and blotted onto nitrocellulose membranes (Macherey-Nagel,
Du¨ren, Germany) and probed with the antibodies listed in the
Table S1. Signals were detected using ECL substrate solution [33]
and recorded with Fusion-SL 3500 WL image acquisition system
(Vilber Lourmat, Marne-la-Valle´e, France).
siRNA-mediated Gene Silencing
All siRNAs used in the study were synthesized by Dharmacon
(Thermo Fisher Scientific, Epsom, UK) and resuspended in the 1x
siRNA Buffer (Dharmacon). Unless indicated otherwise, cells were
seeded one day before transfection at the confluence of 50–70%.
siRNA transfection was performed using Lipofectamine RNAi
Max (Life Technologies) according to the manufacturer’s instruc-
tions. Transfection complexes were prepared in serum-free
OptiMEM medium (Gibco) and added to a complete growth
medium in 20:80 v/v proportion. Final concentrations of siRNAs
were 50 nM (non-targeting pool siRNA,ERG siRNA) or 25 nM
(TDRD1 siRNAs). All siRNA used in the study are listed in the
Table S1.
CpG Island Definition and Bisulfite DNA Sequencing
TDRD1-promoter associated CpG island was defined according
to the default criteria provided by UCSC Genome Browser
(http://genome.ucsc.edu/). Genomic DNA was extracted from
cells using QIAamp DNA blood Mini Kit (Qiagen). Sodium
bisulfite conversion of DNA was performed with the EpiTect
Bisulfite Kit (Qiagen) using 1mg of genomic DNA. The 525-bp
DNA fragment containing the TDRD1 promoter-associated CpG-
island was amplified with HotStarTaq DNA Polymerase (Qiagen)
using primers listed in Table S1. The PCR product was cloned
into pCR2.1 vector using TOPO TA cloning kit (Life Technol-
ogies). TOP10 chemically competent cells (Life Technologies)
were transformed with the ligation product. After blue-white
screening, plasmids from the colonies containing the insert were
subjected to Sanger sequencing (GATC, Konstanz, Germany).
Raw Sanger sequencing reads were analyzed for methylation
events using the online tool BISMA [34].
5-aza-29-deoxycytidine Treatment
LNCaP or VCaP cells were seeded onto poly-L-lysine (Sigma-
Aldrich) coated 12-well plates at low density. As of the following
day, cells were treated with vehicle (0.1% DMSO, Applichem,
Darmstadt, Germany) or the indicated concentrations of 5-aza-29-
deoxycytidine (Sigma-Aldrich) for five consecutive days. Every
24 h, growth medium was replaced with a freshly-prepared
medium containing either 5-aza-29-deoxycytidine or vehicle.
Cell Viability Assay
For the viability assay, 2.5x104 VCaP cells were seeded in black
bottom 96-well plates (Perkin Elmer, Waltham, MA, USA) in 80ml
of the normal growth medium. After 24 h, cells were transfected
with siRNAs as described above and this day was referred to as
‘‘day 1’’. Cell viability was assessed with the CellTiter-Blue Cell
Viability Assay (Promega Corporation, WI, USA) on days 1, 3, 5,
7 and 9 according to the manufacturer’s instructions. Fluorescence
was recorded with Tecan Infinite M200 plate reader (Tecan
Group Ltd, Ma¨nnedorf, Switzerland).
Statistical Data Analysis
All data were analysed using GraphPad Prism 5.04. Quantita-
tive data are shown as mean 6 SEM (standard error of the mean)
calculated from all performed experiments, unless indicated
otherwise. All comparisons between experimental groups were
performed by Mann-Whitney-Wilcoxon test with Bonferroni
correction (* P,0.05, ** P,0.01, *** P,0.001, **** P,0.0001).
Spearman (r) and Pearson (r) correlation coefficients were
calculated with GraphPad Prism 5.04.
Results
TDRD1 is Co-expressed with ERG but not with ETV1 in
Human Prostate Cancer
Our previous expression profiling study of human prostate
cancer specimens revealed that TDRD1 is, apart from ERG, the
most differentially expressed gene between TMPRSS2:ERG-nega-
tive and -positive tumors [16]. We thus performed a correlation
analysis on the data from 93 prostate tissue samples (46 benign, 30
TMPRSS2:ERG-negative, 17 TMPRSS2:ERG-positive prostate
tumors) and found that mRNA levels of ERG and TDRD1
measured by Human Exon 1.0 ST Array are remarkably
correlated across all samples (r2 = 0.84), suggesting a mechanistic
link between the two genes. In contrast, TDRD1 was not co-
expressed with ETV1 (r2 = 0.05) which is an ETS transcription
factor found to be sporadically rearranged in prostate cancer. To
corroborate these observations, we measured TDRD1, ERG and
ETV1 mRNA levels with quantitative RT-PCR in the same set of
samples. Again, TDRD1 expression was found to correlate with
ERG (r2 = 0.77), but not with ETV1 (r2,0.01) expression (Fig. 1a).
To provide an independent validation of our findings, we queried
the Oncomine database [35] using ‘‘TDRD1’’ and ‘‘prostate
cancer’’ as search terms. The analysis of two identified studies
supports our observations: in the data of Grasso et al. [36] ERG
was the topmost gene co expressed with TDRD1. In the data of
Taylor et al. [17], TDRD1 was found to be co expressed with ERG
(r2 = 0.55) but not with ETV1 (r2 = 0.02) across 149 primary
prostate tumors. To explain the observed co-expression, we
employed cellular models of prostate cancer, including cells
representing benign (RWPE-1, BPH-1), fusion-negative (PC-3,
DU145), ERG-rearranged (VCaP, NCI-H660) and ETV1-rearranged
(LNCaP) prostate cancer. Gene expression measurements in prostate
cell lines showed that while TDRD1 mRNA levels were independent
of ETV1 expression, an evident association exists between TDRD1
and ERG expression in vitro (Fig. 1b). None of the cell lines without
ERG overexpression expressed TDRD1, while NCI-H660 and VCaP
cell lines, both of which harbor the TMPRSS2:ERG fusion, expressed
high levels of TDRD1 (Fig. 1b). We then asked if the high levels of
both TDRD1 and ERG messenger RNA in ERG-positive prostate
cells translate into considerable amounts of the respective proteins
and found that VCaP cells express ERG and TDRD1 at levels
detectable by western blotting (Fig. 1c). Based on these initial results,
we decided to use VCaP cells as an in vitro model to study the
mechanistic relation between ERG and TDRD1 genes in ERG-
rearranged prostate cancer.
TDRD1 is not co-expressed with ERG in Hematopoietic
Cancers
Some hematopoietic cancers overexpress ERG protein [37,38]
and it is known that myeloid, T- and Bcell leukemias depend on
ERG for their maintenance [39,40]. We thus investigated ERG
ERG Activates TDRD1 in Prostate Cancer
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Figure 1. TDRD1 is co-expressed with ERG but not with ETV1 in prostate cancer. (A) Correlation analysis of mRNA levels measured by qRT-
PCR in TMPRSS2:ERG-negative (ERG-, n = 30) and TMPRSS2:ERG-positive (ERG+, n = 17) prostate cancers as well as adjacent benign prostate tissue
(n = 46). Pearson correlation coefficient is shown. (B) Analysis of mRNA expression in prostate cell lines by qRT-PCR. Two independent experiments
ERG Activates TDRD1 in Prostate Cancer
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and TDRD1 co-expression by qRT-PCR in a panel of cell lines
representing various hematopoietic cancers. Although we detected
high levels of ERG mRNA in several cancer cell lines derived from
the hematopoietic lineage, the corresponding expression of
TDRD1 mRNA was approximately 50-fold lower than in VCaP
cells (Fig. 1d). To extend our analysis beyond cell lines, we
compared ERG and TDRD1 mRNA expression in prostate tissues
and in cytogenetically abnormal acute myeloid leukemia (CA-
AML) measured by the same platform (Human Exon 1.0 ST
Array) [41]. In contrast to our observations in prostate cancer
(r2 = 0.84), ERG and TDRD1 were not co-expressed in CA-AML
(r2 = 0.07). ERG has also been reported to be overexpressed in
Ewing’s sarcomas [42–45]. We thus analyzed the available gene
expression profiling studies of Ewing’s sarcoma tumors for TDRD1
and ERG expression [46,47]. In contrast to prostate cancer, there
was no co-expression of ERG and TDRD1 in any of these studies
(r2 = 0.03 and 0.02, respectively). This suggests that the co-
expression of ERG and TDRD1 is specific for prostate cancer.
ERG Transcription Factor is Required to Maintain High
TDRD1 Expression in TMPRSS2:ERG-positive Cells
Co-expression of two genes can be explained by, among others,
regulation of one of the genes by the other or by their mutual
regulation in a feed-forward loop. To test these possibilities, we
depleted either ERG or TDRD1 protein in VCaP cells by RNA
interference and determined mRNA and protein expression of
both genes. Silencing of ERG with 80% efficiency resulted in 3.9-
fold downregulation of TDRD1 mRNA 72 h post-transfection
(P,0.0001, Fig. 2a). In contrast, silencing of TDRD1 did not result
in any changes in ERG mRNA expression. Analysis of the
corresponding protein levels by western blot revealed that
silencing of ERG and TDRD1 genes was very effective, leading
to a complete depletion of both proteins from the cells (Fig. 2b).
While knockdown of ERG caused a profound downregulation of
TDRD1 protein at 72 h, no such effects on ERG were detected
after silencing of the TDRD1 gene. A similar expression pattern
was also observed at 48 h after transfection (data not shown). In
conclusion, a constant presence of ERG is required to maintain
high expression of TDRD1 in VCaP cells and the observed co-
expression of the two genes in prostate tumors could be explained
by a unidirectional activation of TDRD1 through the ERG
transcription factor.
TDRD1 Promoter-associated CpG Island is
Hypomethylated in TMPRSS2:ERG-positive Prostate
Tumors
Expression of TDRD1, along with that of other germ line-
specific genes, is known to be repressed in somatic tissues by
epigenetic silencing [26,48]. We therefore investigated methylation
status of the TDRD1 promoter and the associated CpG island in
the context of ERG rearrangements. We inspected methylation of
DNA around the TDRD1 transcription start site in prostate
tumors, that we had analyzed by MeDIP-Seq [22], and found this
region to be differentially methylated between tumors with and
without the TMPRSS2:ERG gene fusion. Specifically, the 1 kb
region spanning the TDRD1 promoter-associated CpG island was
significantly hypomethylated in the TMPRSS2:ERG-positive tu-
mors compared to benign and TMPRSS2:ERG-negative tumors
(P,0.0001, Fig. 3a). A 500-bp window immediately downstream
of the CpG island did not show differences in DNA methylation
between ERG-negative and ERG-positive tumors (P = 0.41,
Fig. 3a). Moreover, DNA sequence flanking the putative TDRD1
promoter was not differentially methylated between any of the
three groups (P.0.05), indicating that the differential DNA
methylation occurs in the direct proximity of the TDRD1
transcriptional start site but not around it. Of note, the average
level of TDRD1 promoter methylation was inversely correlated
with TDRD1 mRNA levels across all 93 samples (r= -0.57),
suggesting that loss of promoter methylation substantially contrib-
utes to TDRD1 overexpression in TMPRSS2:ERG fusion-positive
prostate cancer (Fig. 3b).
ERG-induced Loss of Epigenetic Repression at the TDRD1
Promoter is a Major Mechanism of TDRD1 Activation
Since the differentially methylated region spanned the CpG
island associated with the TDRD1 promoter and CpG islands are
known to play a role in regulating transcription [49], we have
performed bisulfite sequencing of the TDRD1-associated CpG
island in prostate cell lines. We found that the CpG island was fully
methylated in benign cells and ERG-negative cancer cell lines,
with an average methylation ranging from 89.3% for LNCaP to
98.6% for PC-3 (Fig. 4a). In contrast, CpG methylation was
almost completely absent in the TMPRSS2:ERG-positive cell lines
NCI-H660 and VCaP (11.4% and 0.7%, respectively). Compar-
ison of TDRD1 mRNA levels (Fig. 1b) to the DNA methylation of
the CpG-island at the TDRD1 promoter (Fig. 4a) revealed an
inverse correlation between the two parameters across the
investigated cell lines, which was in accordance with the
corresponding data from prostate tumors. Given the stark
differences in DNA methylation at the TDRD1 promoter between
the ERG-rearranged and remaining cell lines, we hypothesized
that loss of DNA methylation at the TDRD1 promoter is the major
mechanism responsible for TDRD1 activation. To test this
possibility, we treated ERG-negative LNCaP cells with the DNA
methyltransferase inhibitor 5-aza-deoxycytidine (decitabine; [50]).
After five days of treatment with submicromolar concentrations of
decitabine we observed a dose-dependent increase in expression of
GSTP1 gene which is known to be silenced by methylation in
LNCaP cells [51] (Fig. 4b). Notably, TDRD1 mRNA was
upregulated by more than 25-fold. Consequently, following the
increase in TDRD1 mRNA levels, TDRD1 protein became
detectable in LNCaP cells by immunoblotting (Fig. 4b, insert),
Indicating that loss of DNA methylation may indeed be sufficient
to drive TDRD1 expression.
To check if ERG can mimic the effects exerted on TDRD1
expression by demethylation of the LNCaP genome, we generated
stable LNCaP cells overexpressing coding sequence of the
TMPRSS2:ERG fusion T1/E4 in an inducible manner. Induction
of ERG expression with doxycycline led to an almost 5-fold
increase in TDRD1 mRNA, while doxycycline had no influence on
TDRD1 expression in the LNCaP clone carrying the empty
expression vector (Fig. 4c). We have used bisulfite sequencing to
analyze the corresponding DNA methylation status of the TDRD1
promoter-associated CpG island upon ERG induction. ERG
overexpression led to the hypomethylation of the TDRD1
were performed in triplicate. Human testis RNA was used as positive control for TDRD1 expression. (C) Analysis of protein expression in prostate cell
lines by western blotting. (D) Analysis of mRNA expression in hematopoietic cancer cell lines by qRT-PCR. Two independent experiments were
performed in triplicate.
doi:10.1371/journal.pone.0059976.g001
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promoter region in 27% of the investigated alleles, while we did
not observe any hypomethylation upon doxycycline treatment in
the empty vector control (Fig. 4d, Fig. S1a). Given that the
converse experiment, i.e. depletion of ERG in VCaP cells by
RNAi, has led to downregulation of TDRD1 expression (Fig. 2) we
have also performed bisulfite sequencing of the TDRD1 CpG
island after ERG silencing in VCaP cells. At 96 h post-
transfection, silencing of ERG with 65% efficiency resulted in
almost 3-fold increase in mean DNA methylation at the CpG
island, from 15.7% of methylated CpGs in non-targeting control
to 45% in cells treated with siRNA targeting ERG (Fig. 4e, Fig.
S1b).
The above mentioned observations demonstrate that DNA
methylation status of the TDRD1 promoter and thus its
transcriptional activity are mechanistically linked to the levels of
ERG transcription factor in prostate cancer cells.
Differential Role of TDRD1 in Testis and Prostate Cancer
The evolutionary conserved piRNA pathway plays an impor-
tant role in male germline during spermatogenesis [52–54]. The
components of the piRNA pathway act to suppress the activity of
transposable elements, potentially in order to maintain the
integrity of the germline chromosomes during genome-wide
demethylation in primordial germ cells [55–57]. Studies per-
formed in mouse and zebrafish have shown that Tdrd1, ortholog
of human TDRD1, is a component of the piRNA pathway which
specifically interacts with piRNA-associated proteins to potentiate
the piRNA-mediated silencing of LINE1 retrotransposons.
Accordingly, loss of Tdrd1 in mouse was shown to result in
LINE1 derepression [27,58]. In humans, four orthologs coding for
piRNA-associated proteins exist: PIWIL1-PIWIL4 [59]. To test if
TDRD1 may interact with PIWI proteins in TMPRSS2:ERG-
positive prostate cancer and thus contribute to the piRNA
pathway activity, we measured the mRNA expression of human
PIWIL genes in prostate cancer cell lines (Fig. 5a). mRNA
expression of PIWIL1-PIWIL4 genes was undetectable by qRT-
PCR in most of the prostate cell lines investigated. In cell lines with
a detectable expression, PIWIL mRNA levels were .500-fold
lower than in testis, which was used as a positive control, thus
making it unlikely that the piRNA pathway is functional in
prostate cancer cells. Despite hardly detectable PIWIL1-4 expres-
sion, we decided to test the extent of TDRD1 influence on LINE1
retrotransposition activity in prostate cancer cells. We have
measured mRNA expression of the LINE1-encoded endonuclease
(L1 ORF2), which we used as an approximation for LINE1
activity, after TDRD1 depletion in VCaP cells. As a positive
control for our assay, we observed a dose-dependent induction of
L1 ORF2 upon treatment of LNCaP cells with increasing
concentrations of the demethylating agent decitabine (Fig. 5b).
However, even after prolonged (8 days) and effective TDRD1
silencing in VCaP cells we observed no significant differences in
LINE1 expression (Fig. 5c), indicating that TDRD1 abundance
does not control LINE1 activity in TMPRSS2:ERG-positive
prostate cancer cells. Moreover, in contrast to silencing of ERG,
which is known to negatively influence in vitro growth of VCaP
cells, silencing of TDRD1 did not have any impact on VCaP cell
viability (Fig. 5d). Accordingly, overexpression of TDRD1 in
ERG-negative LNCaP cells did not lead to changes in cell viability
(data not shown), suggesting that expression of TDRD1 is not
required for proliferation of ERG-rearranged prostate cancer cells
in vitro.
Discussion
Previous studies have identified TDRD1 as the most differen-
tially expressed gene between ERG-negative and ERG-positive
prostate tumors besides ERG [16,23,60,61]. Herein, we describe
the co-expression of ERG and TDRD1 in prostate cancer in vitro
and in vivo. We demonstrate that TDRD1 expression is induced by
the ERG transcription factor in TMPRSS2:ERG-rearranged
prostate cells. We show that the TDRD1 promoter is hypomethy-
lated in TMPRSS2:ERG-rearranged tumors and cell lines and
report that the DNA methylation inversely correlates with TDRD1
expression in vivo. In these regards, our data extend and
corroborate the findings of a recently published study [61]. In
addition, we functionally link ERG rearrangements to TDRD1
overexpression by presenting mechanistic evidence that it is the
accumulation of ERG which leads to loss of the DNA methylation
at the TDRD1 promoter. Thus, we propose the existence of ERG-
induced epigenetic activation of gene expression.
Figure 2. ERG transcription factor is required to maintain high TDRD1 expression. (A) ERG and TDRD1 mRNA expression levels in VCaP cells
measured 72 h after gene silencing with siRNAs. Three independent experiments were performed in triplicate. (B) ERG and TDRD1 protein expression
in VCaP cells 72 h after gene silencing with siRNAs.
doi:10.1371/journal.pone.0059976.g002
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Our data suggest that activation of TDRD1 transcription is a
consequence of ERG but not of ETV1 rearrangements. This is in
agreement with the data by Paulo et al., who experimentally
classified genes differentially expressed in fusion-positive primary
prostate tumors into three distinct categories: ERG-targets, ETV1-
targets and overlapping targets and showed that TDRD1 belongs
to the first category [61]. Similarly to Paulo et al., we have also
found an inverse correlation between TDRD1 expression and
DNA methylation of the TDRD1 promoter in vitro and in vivo. A
restricted tissue expression pattern of TDRD1 (expressed in the
germline and silent in adult somatic tissues [26,62]) is likely
governed by extensive methylation of the TDRD1 promoter-
associated CpG island [26]. This view is further supported by a
repression of TDRD1 expression accompanied by complete CpG
methylation in benign prostate tissues and fusion-negative prostate
cancer. Our data shows that it is either ERG or factors acting
downstream of ERG which are responsible for the loss of DNA
methylation at the TDRD1 promoter observed in TMPRSS2:ERG-
positive tumors. We present two independent experimental proofs
of the statement above: i) forced expression of ERG in LNCaP
cells is sufficient to activate TDRD1 expression and is accompanied
by a loss of DNA methylation at the TDRD1 promoter, ii) ERG
silencing in VCaP cells is sufficient to restore the tissue-specific
methylation status at the TDRD1 promoter and is accompanied by
a repression of TDRD1 transcription. Given that ERG was shown
to bind DNA upstream of the TDRD1 transcription start site [61]
and that transcription factor binding was suggested to exert a
protective role against CpG island methylation [48,63], we
propose a model in which ERG binding leads to loss of DNA
methylation at the TDRD1 promoter. This could be accomplished
by two alternative modes of action: active, in which ERG recruits
enzymatic activities to remove DNA methylation or passive, in
which ERG competes with DNA methyltransferases for their
binding sites in the proximity of TDRD1 promoter, thereby
preventing maintenance of DNA methylation during DNA
replication. In this context, it is interesting to note that a recently
published study reported TDRD1 promoter to be hypermethylated
in infertile male patients with spermatogenic disorders [64], linking
TDRD1 promoter methylation and TDRD1 expression to human
disease.
Close inspection of data reveals that in several prostate tumors
tested negative for the TMPRSS2:ERG rearrangement, TDRD1 is
Figure 3. TDRD1 promoter associated CpG island is hypomethylated in TMPRSS2:ERG-positive prostate cancer. (A) Analysis of TDRD1
promoter methylation in prostate tumors by MeDIP-Seq. The values represent the average degree of DNA methylation of the 500-bp bins. (B)
Correlation analysis of TDRD1 promoter methylation and TDRD1 mRNA expression in prostate cancer. The Spearman correlation coefficient is shown.
doi:10.1371/journal.pone.0059976.g003
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expressed at high levels despite low ERG expression, suggesting
that ERG may not be the only factor which is capable of activating
TDRD1 transcription. Such ERGlow/TDRD1high tumors were also
reported by Taylor et al. [17]. ERG-independent induction of
TDRD1 could also explain the apparently counter intuitive
observation that in NCI-H660 cells the TDRD1 promoter is
hypomethylated, despite the absence of detectable ERG protein.
Thus, the possibility of other factors controlling TDRD1 expression
in prostate cancer cells cannot be excluded.
One of the important questions brought up by this study
concerns the consequences of TDRD1 accumulation in ERG-
rearranged prostate cancer. Our findings suggest that TDRD1
Figure 4. ERG-induced loss of epigenetic repression at the TDRD1 promoter is a major mechanism of TDRD1 overexpression. (A) DNA
methylation analysis of the TDRD1 promoter-associated CpG island in prostate cell lines by bisulfite sequencing. Average methylation level of the
whole CpG island calculated from five sequenced colonies is shown (%). (B) Analysis of mRNA expression in LNCaP cells after treatment with the
demethylating agent 5-aza-29-deoxycytidine. Insert: analysis of protein expression in LNCaP cells after treatment with 5-aza-29-deoxycytidine. 75mg of
protein lysate from LNCaP cells was used per lane. (C) Analysis of mRNA expression in stable LNCaP clones overexpressing ERG. Two independent
experiments were performed in triplicate. Insert: ERG expression analysis at 48 h in LNCaP clones by western blotting. (D) Bisulfite sequencing of the
TDRD1 promoter-associated CpG island in LNCaP cells 48 h after induction of ERG expression with doxycycline. (E) Bisulfite sequencing of the TDRD1
promoter-associated CpG island 96 h after silencing of ERG in VCaP cells. The data shown in (D) and (E) are mean % of methylation of the entire CpG
island calculated from 11–12 sequenced clones.
doi:10.1371/journal.pone.0059976.g004
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does not contribute to the control of LINE1 activity in prostate
cancer cells, as it is unlikely that the piRNA pathway is functional
these cells. Despite the fact that TDRD1-interacting proteins have
not been identified in humans, a human ortholog (PIWIL2) of a
mouse gene coding for a Tdrd1-interacting protein (Mili) is either
not-expressed or expressed at very low levels in prostate cell lines.
Furthermore, silencing of TDRD1 or ERG did not influence the
activity of LINE1 elements. In addition, we did not observe
TDRD1 to be essential for viability and proliferation of prostate
cancer cells in vitro. While it is conceivable that TDRD1 expression
confers a selective advantage to prostate cancer cells only in vivo,
we cannot exclude that the impact of TDRD1 silencing on cell
viability in vitro may be masked by the expression of another
protein with a redundant function. Irrespective of the possible
functional involvement of TDRD1 in prostate cancer, TDRD1
overexpression has a potential of being exploited in prostate
cancer therapy. It is well established that ERG expression is not
entirely specific to ERG-rearranged prostate cancer cells: ERG is
known to be expressed in endothelial cells and in the hematopoi-
etic lineage. In contrast, as a cancer/testis antigen, TDRD1 is not
expressed in healthy somatic tissues. TDRD1 expression in
testicular tissue does not constitute a potential risk of the off-
target activity for immunotherapy due to the immunological
privilege of testis. We thus propose that overexpression of TDRD1,
observed by us and others in 100% of TMPRSS2:ERG-positive
prostate tumors, makes TDRD1 a promising target for immuno-
therapy of ERG rearrangement-positive prostate cancer.
In conclusion, we report here that overexpression of ERG
transcription factor in TMPRSS2:ERG-positive prostate cancer
induces a loss of DNA methylation at the TDRD1 promoter-
associated CpG island. By providing the evidence of a mechanistic
link between ERG and methylation we uncover a previously
undescribed phenomenon of ERG-induced epigenetic gene
activation. Finally, our data suggest that TDRD1 overexpression
in ERG-rearranged prostate cancer has a potential of being
exploited as a target for prostate cancer immunotherapy.
Supporting Information
Figure S1 Levels of ERG modulate DNA methylation at
the TDRD1 promoter in prostate cancer cells. Bisulfite
sequencing of the TDRD1 promoter-associated CpG island (A)
48 h after induction of forced ERG expression in LNCaP cells or
(B) 96 h after knockdown of ERG by RNAi in VCaP cells. Each
circle represents a single CpG dinucleotide of the CpG island




Figure 5. TDRD1 does not control LINE1 activity in TMPRSS2:ERG-positive VCaP cells. (A) mRNA expression analysis of PIWIL genes in
prostate cell lines by qRT-PCR. Testis RNA was used as a positive control. (B) mRNA expression analysis of LINE1 ORF2 in VCaP cells following 5 days of
treatment with 5-aza-29-deoxycytidine. (C) mRNA expression analysis of LINE1 ORF2 in VCaP cells following prolonged (8 days) ERG or TDRD1
silencing. (D) Metabolic viability assay of VCaP cells treated with siRNAs. One (B), two (A) or three (C, D) independent experiments were performed in
triplicate.
doi:10.1371/journal.pone.0059976.g005
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